BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260721
DTEND;VALUE=DATE:20260724
DTSTAMP:20260515T035309
CREATED:20260430T111342Z
LAST-MODIFIED:20260430T111342Z
UID:43429-1784592000-1784851199@www.pharmajournalist.com
SUMMARY:9th International Neoantigen Summit
DESCRIPTION:As the only conference focused on neoantigens\, the 9th International Neoantigen Summit returns to Amsterdam as the most timely and essential gathering for the field. As your only chance this year to learn about the latest clinical data in the field and address the full translational journey – from antigen identification and validation through to biomarker strategy\, clinical trial readouts and therapeutic efficacy – it’s not one to miss. \nWith a sharp focus on optimising translational testing\, strengthening neoantigen validation and advancing novel personalised and off‑the‑shelf approaches\, the conference is designed to help the industry streamline clinical trials and develop durable therapies with high immune response. \nOver 3 immersive days\, the summit will unite 70+ C‑level executives\, directors\, heads and senior scientists from leading biopharma organisations across Europe and the US. Attendees span: \n\nCancer immunotherapy\nAntigen discovery\nBioinformatics\nAI‑driven validation\nPreclinical and clinical development\nRegulatory strategy\n\nAll brought together by a shared mission to unlock the full potential of neoantigen‑targeted therapies. \nWith 6 new speaking companies\, including Black Canyon Bio\, CellVax Therapeutics\, Echo Immune\, Epitopea\, Khosen Bio and Treos Bio\, the summit convenes industry pioneers including Nykode Therapeutics\, Evaxion\, Geneos\, and other leading innovators shaping the next generation of immunotherapies. Every session is curated for relevance\, and every interaction is designed to foster meaningful collaboration. \nParticipants can expect critical clinical data updates\, practical insights into bioinformatics and AI applications\, strategies for clinical trial design and execution\, and guidance on translating preclinical findings into successful clinical outcomes. More than a conference\, this is the only annual checkpoint for the neoantigen community – a one‑stop platform to benchmark progress\, uncover breakthroughs and build the partnerships that will drive the next wave of neoantigen‑targeted therapies forward.
URL:http://www.pharmajournalist.com/event/9th-international-neoantigen-summit/
LOCATION:Park Plaza Amsterdam Victoria\, Damrak 1-5\, 1012 LG\, Amsterdam\, Netherlands
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260728
DTEND;VALUE=DATE:20260731
DTSTAMP:20260515T035309
CREATED:20260312T131240Z
LAST-MODIFIED:20260312T131240Z
UID:43114-1785196800-1785455999@www.pharmajournalist.com
SUMMARY:4th ADC Linker & Conjugation Summit
DESCRIPTION:4th ADC Linker & Conjugation Summit\nLinking Chemistry to Clinical Success Through Better ADC Design \n\nWhen? July 28-30\, 2026\nWhere? Boston\, MA\n\nADC development is evolving fast\, with developers pushing beyond traditional cytotoxins into dual‑payload constructs\, high‑DAR species\, degrader–antibody conjugates\, and next‑generation modalities. This surge in innovation is placing new pressure on linker architecture and conjugation chemistry to improve stability\, reduce off‑target toxicity\, and maintain manufacturability at scale. \nThe 4th ADC Linker & Conjugation Summit returns this July as the only meeting dedicated exclusively to overcoming these chemistry‑centric challenges. Built specifically for ADC chemists\, protein engineers\, and bioconjugation specialists\, the summit offers a highly curated setting where every session speaks directly to the scientific bottlenecks shaping next‑generation ADC performance. Attendees join peers with the same technical focus\, ensuring every conversation is relevant and grounded in real‑world ADC development needs.Across three focused days\, more than 80 scientific experts will dissect the mechanisms driving linker stability\, conjugation precision\, and payload behavior. The program features 20+ industry‑led case studies covering homogeneous ADC design\, controlling premature payload release\, dual‑payload engineering\, hydrophobicity‑driven aggregation\, and the integration of predictive modeling into conjugation strategies. These sessions reflect broader industry priorities\, where site‑specific conjugation\, next‑generation linkers\, and stability optimization remain top areas of innovation. \nThis year introduces expanded workshops and interactive debates\, including new sessions examining how to more effectively connect linker chemistry to translational outcomes and how to redesign payloads using emerging linker technologies. The 2026 meeting also welcomes 17 new speakers from 13 new companies\, offering fresh insight into the rapidly diversifying toolkit available for ADC design. \nFor scientists working at the core of ADC chemistry\, this summit provides a rare opportunity to benchmark strategies\, challenge assumptions\, and contribute to the next decade of linker and conjugation innovation. \nView the full program and explore the 2026 agenda \nDownload the event guide here: https://ter.li/7pj7r6
URL:http://www.pharmajournalist.com/event/4th-adc-linker-conjugation-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260728
DTEND;VALUE=DATE:20260731
DTSTAMP:20260515T035309
CREATED:20260326T114512Z
LAST-MODIFIED:20260326T114512Z
UID:43226-1785196800-1785455999@www.pharmajournalist.com
SUMMARY:5th In Vivo Cell Engineering & Gene Editing Summit
DESCRIPTION:The 5th In Vivo Cell Engineering & Gene Editing Summit returns as the leading industry meeting dedicated to advancing the next generation of in vivo delivery platforms\, gene editing tools\, and translational strategies that support safe\, precise\, and scalable genetic medicines. Designed for scientists\, technical leaders\, and strategic decision-makers across biopharma\, this summit provides a focused forum to exchange practical insights that directly influence scientific and clinical progress. \nThis year’s faculty brings together experts from cutting-edge biotechnology companies and global pharmaceutical organizations\, including leaders from AstraZeneca\, Pfizer\, Eli Lilly\, Ensoma\, Capstan Therapeutics\, Verve Therapeutics\, nChrioma Bio\, and more. Their collective experience spans delivery system innovation\, payload engineering\, translational development\, and early clinical execution\, giving delegates a clear view of what is required to successfully advance in vivo platforms. \nOver three days of data-driven discussion\, attendees will explore the latest advancements in lipid nanoparticle engineering\, viral and nonviral vector optimization\, capsid evolution\, and emerging delivery technologies for targeted\, efficient editing. Sessions will detail how teams are engineering payloads to enhance potency\, durability\, safety\, and manufacturability. Speakers will also share frameworks for designing rigorous preclinical packages that address biodistribution\, immunogenicity\, and off-target risk early in development. \nThe summit places a strong focus on translational and early clinical learnings\, with case studies that reveal how organizations are approaching dose selection\, biomarker development\, patient monitoring\, and regulatory positioning. These insights provide an unfiltered look at what has worked in real programs and how teams are adjusting strategies to improve clinical readiness. \nDelegates will benefit from a mix of scientific depth and strategic clarity. Whether you are building new delivery platforms\, advancing editing tools\, refining analytical approaches\, or preparing a therapy for first-in-human studies\, this meeting helps you benchmark your progress and sharpen decision-making. \nJoin peers who are driving the future of in vivo gene editing and cell engineering. This summit delivers the connections\, evidence-based insights\, and collaborative environment needed to progress transformative genetic medicines. \nTo learn more and register online\, please click here.
URL:http://www.pharmajournalist.com/event/5th-in-vivo-cell-engineering-gene-editing-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260811
DTEND;VALUE=DATE:20260814
DTSTAMP:20260515T035309
CREATED:20260429T095446Z
LAST-MODIFIED:20260429T095446Z
UID:43402-1786406400-1786665599@www.pharmajournalist.com
SUMMARY:3rd Lab Ops & Facility Management for Biopharma West Summit
DESCRIPTION:The 3rd Annual Lab Ops & Facility Management for Biopharma West Summit is the West Coast’s dedicated meeting for Lab Operations and Facilities leaders who are being asked to do more with less while keeping scientists productive and R&D environments running at the highest standard. With tighter budgets\, workforce fluctuations\, and rapid pipeline shifts reshaping day-to-day priorities\, this summit is built to help teams maintain operational excellence without compromising safety\, compliance\, or lab uptime. \nTaking place August 11–13\, 2026 in San Diego\, the program brings together 70+ senior leaders across lab operations\, facilities\, scientific services\, and operational support from fast-growing biotechs\, established pharma\, and leading CDMOs/CROs. Expect operator-led discussions centered on the decisions Lab Ops teams are making right now: how to prioritize when everything feels urgent\, how to streamline workflows to protect throughput\, and how to build resilient support models that hold up through organizational change. \nThe agenda tackles the themes shaping lab performance in 2026. You’ll explore how teams are building resilient operations in volatile environments\, integrating automation and applied AI to reduce manual burden and improve decision-making\, and strengthening vendor partnerships and procurement strategy to spend with intention while reducing downtime risk. You’ll also hear how organizations are planning flexible lab and facility footprints that can adapt as research needs evolve\, including approaches to facility transitions and future-proofing infrastructure. \nA key feature is the pre-conference workshop day\, featuring two hands-on sessions designed for immediate application. Workshop A provides a practical toolkit for implementing AI in lab operations\, with proven use cases and guidance for integrating tools into existing systems without disrupting daily work. Workshop B dives into vendor strategy to reduce spend and maximize operational leverage\, with actionable approaches to consolidation\, identifying cost-saving opportunities\, and maintaining service excellence. \nWith 20+ expert speakers\, two interactive workshops\, and 6+ hours of dedicated networking\, this summit is built for honest benchmarking\, meaningful connections\, and takeaways you can implement immediately to maintain excellence and better support scientists. \nTo know more visit: https://ter.li/jgbff6e1
URL:http://www.pharmajournalist.com/event/3rd-lab-ops-facility-management-for-biopharma-west-summit/
LOCATION:The Westgate Hotel\, 1055 2nd Ave\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260819
DTEND;VALUE=DATE:20260822
DTSTAMP:20260515T035309
CREATED:20260430T095421Z
LAST-MODIFIED:20260430T095421Z
UID:43423-1787097600-1787356799@www.pharmajournalist.com
SUMMARY:6th Oligonucleotides for CNS Summit
DESCRIPTION:The 6th Annual Oligonucleotides for CNS Summit USA returns to Boston on 19–21 August 2026\, uniting 160+ leaders across pharma and biotech to accelerate the discovery\, translation and clinical success of CNS‑targeted oligonucleotide therapies. As advances in RNA chemistry\, delivery technologies and clinical evidence unlock previously undruggable CNS targets\, this meeting is the industry’s most focused forum to benchmark what is truly working — and what’s next. \nAcross three highly interactive days\, hear the latest data and strategy from companies including Eli Lilly\, Stoke Therapeutics\, Dyne Therapeutics\, Creyon Bio and Quiver Bioscience\, covering ASOs\, siRNAs\, saRNAs and aptamers. Dive into real‑world challenges around CNS penetration\, BBB shuttles\, intrathecal vs systemic delivery\, splice modulation\, chemistry and conjugation design\, PK/PD translation\, safety and regulatory alignment — all through case studies\, panels\, workshops and roundtables designed for open\, precompetitive discussion. \nWith expanding pipelines\, growing competition and rising expectations for clinical impact beyond rare disease\, this summit offers a uniquely concentrated environment to learn from clinical‑stage programs\, stress‑test your development strategy and connect with the scientists and decision‑makers shaping the future of CNS oligonucleotides. \nFind out more today – https://ter.li/twgv2av6
URL:http://www.pharmajournalist.com/event/6th-oligonucleotides-for-cns-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260909
DTEND;VALUE=DATE:20260911
DTSTAMP:20260515T035309
CREATED:20260512T104607Z
LAST-MODIFIED:20260512T104607Z
UID:43492-1788912000-1789084799@www.pharmajournalist.com
SUMMARY:6th iPSC Drug Development Summit
DESCRIPTION:As iPSC therapies transition from promise to clinical reality\, the 6th iPSC Drug Development Summit arrives at a pivotal moment for biopharma leaders advancing next-generation cell therapies. Bringing together senior scientists\, CMC experts\, and decision-makers\, this industry-focused meeting is dedicated exclusively to accelerating iPSC-based drug development from discovery through clinical translation and commercialization. \nThis year’s agenda is designed to address the most pressing challenges across the iPSC pipeline\, with a sharp focus on scalability\, manufacturability\, and regulatory alignment as therapies move toward late-stage clinical success. Attendees will gain practical insights across two core tracks\, covering preclinical development and process development & CMC\, including genome editing strategies\, donor and cell line selection\, functional quality control\, and GMP-ready manufacturing approaches. \nThe summit features 25+ expert speakers from leading organizations actively advancing iPSC therapies across indications such as Parkinson’s disease\, diabetes\, oncology\, and ocular disorders. \nSpeaker highlights include: \n\nYanzheng Liu\, Senior Director\, Aspen Neuroscience\nRachel Knopp and Yongting Wang\, Astellas Pharma\nWilliam Hendriks\, Director of PSC Biology\, BlueRock Therapeutics\nEric Law\, Head of CMC Regulatory Affairs\, Century Therapeutics\nAlex Ng\, Chief Scientific Officer\, GC Therapeutics\nMarcella Garita-Hernandez\, Head of iPS Core\, Harvard Medical School\n\nWith contributions from organizations including Astellas Pharma\, BlueRock Therapeutics\, Aspen Neuroscience\, Vertex Pharmaceuticals\, and more\, the meeting provides a unique opportunity to learn directly from teams generating clinical data and overcoming real-world development bottlenecks. \nDesigned for professionals actively building iPSC pipelines\, the summit offers an end-to-end view of the field\, alongside collaborative networking with peers across biopharma\, academia\, and investment. From optimizing early discovery decisions to ensuring commercial readiness\, this is the must-attend forum to benchmark strategies and accelerate the path to clinically successful iPSC therapies. \nFind out more here: https://ter.li/japojzin \nThis meeting is free to attend* for biopharma and academics.
URL:http://www.pharmajournalist.com/event/6th-ipsc-drug-development-summit/
LOCATION:Hyatt Regency Boston Harbor\, 101 Harborside Drive\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260915
DTEND;VALUE=DATE:20260918
DTSTAMP:20260515T035309
CREATED:20260430T095220Z
LAST-MODIFIED:20260430T095220Z
UID:43419-1789430400-1789689599@www.pharmajournalist.com
SUMMARY:9th Neuropsychiatric Drug Development Summit
DESCRIPTION:The Neuropsychiatric Drug Development Summit is the definitive meeting for biopharma leaders shaping the future of psychiatric R&D. At a time of renewed momentum in neuropsychiatry\, this summit brings together senior decision‑makers to redefine how the industry translates science into successful\, patient‑centred therapies. \nAcross discovery\, translational science\, and clinical development\, the agenda showcases the most promising advances in the field — from psychedelics\, muscarinics\, orexins\, and novel neuroplasticity approaches to cutting‑edge translational tools such as EEG\, digital and speech biomarkers\, sleep endpoints\, and smarter patient stratification. Attendees will gain practical insights into overcoming placebo response\, heterogeneity\, and late‑stage failure through biology‑driven\, regulatory‑ready strategies. \nDesigned for meaningful connection and collaboration\, the summit offers an intimate\, highly interactive environment to exchange data\, challenge assumptions\, and build partnerships with peers tackling depression\, schizophrenia\, bipolar disorder\, anxiety\, PTSD\, and addiction. Join the global community accelerating the next era of precision psychiatry. \nFind out more today – https://ter.li/rt2cakk3
URL:http://www.pharmajournalist.com/event/9th-neuropsychiatric-drug-development-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260929
DTEND;VALUE=DATE:20261002
DTSTAMP:20260515T035309
CREATED:20260423T154336Z
LAST-MODIFIED:20260427T150843Z
UID:43381-1790640000-1790899199@www.pharmajournalist.com
SUMMARY:10th IPF Summit
DESCRIPTION:10th Anniversary Edition of the IPF Summit – \nSeptember 29 – October 1\, 2026 | Boston\, MA \nFor a decade\, the IPF Summit has been the go-to\, discussion-led forum uniting stakeholders across the pulmonary fibrosis ecosystem. In its 10th anniversary year\, the stakes\, and the opportunity\, have never been higher. \nFollowing a wave of positive Phase III readouts from leading companies including Bristol Myers Squibb\, United Therapeutics\, and Boehringer Ingelheim\, the field has entered a new era of momentum. But with this progress comes increasing complexity. As standards of care evolve and more therapies emerge\, the question is no longer can we develop treatments\, but how to do so smarter\, faster\, and with meaningful differentiation. \nThe 10th IPF Summit is the only end-to-end\, industry-led meeting designed to tackle this challenge head-on. \nBringing together 150+ experts across discovery\, translational science\, and clinical development\, from organizations including Bristol Myers Squibb\, United Therapeutics\, Boehringer Ingelheim\, Pfizer\, Novartis\, AbbVie\, PureTech Health\, Insilico Medicine\, and many more\, the summit offers a uniquely integrated view of the scientific\, clinical\, and strategic decisions shaping the next decade of IPF innovation. \nAcross dedicated content tracks\, dive into emerging biology and novel targets to unlock new therapeutic avenues\, biomarker-driven and translational strategies to generate clearer signals earlier and next-generation clinical trial design and combination approaches to succeed in an increasingly competitive landscape \nNew for 2026 includes a dedicated ILD & PPF Focus Day\, designed to unpack the complexity of fibrotic lung diseases beyond IPF\, alongside an investor panel offering insight into building conviction and demonstrating differentiated value in an evolving funding environment.\nWith 8+ hours of networking in an intentionally intimate setting\, the summit is built for honest\, high-value discussions\, giving you direct access to the people shaping the future of pulmonary fibrosis drug development. \nWhether you’re advancing early discovery\, translating assets into the clinic\, or positioning therapies in a crowded market\, this is where the field aligns on what success now looks like\, and how to achieve it. \nFind out more about the 10th Anniversary Edition of the IPF Summit: https://ter.li/5ny4yhvk
URL:http://www.pharmajournalist.com/event/10th-ipf-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261012
DTEND;VALUE=DATE:20261016
DTSTAMP:20260515T035309
CREATED:20260512T103447Z
LAST-MODIFIED:20260512T103447Z
UID:43484-1791763200-1792108799@www.pharmajournalist.com
SUMMARY:17th World ADC San Diego
DESCRIPTION:Returning as the largest and definitive ADC congress\, the 17th World ADC San Diego is THE one-stop bioconjugate shop\, bringing together the global ADC community for an unparalleled amalgamation of case studies\, development trends and networking opportunities to forge ADC innovation into differentiated\, early-line patient outcomes. \nWith 7 streams of end-to-end ADC content across Discovery Chemistry\, Discovery Biology\, Preclinical\, Translational Medicine\, Clinical Lessons\, Process & Analytical Development\, and Manufacturing & Supply\, all ADC innovation will be in the spotlight for an unmissable week of data and insights to de-risk future ADC development and push ADCs into earlier line oncology treatments. \nUniting 1\,300 industry senior enthusiasts from biopharma\, innovative start-ups\, leading service providers and academic\, physician and regulator KOLs\, World ADC San Diego is the place to discuss\, debate and advance the future of ADC development. \nFeaturing 170+ senior presenters\, a snapshot of the 2026 speaker faculty includes: \n\nSuzanne Edavettal\, Vice President\, Research & Head\, Protein Therapeutics\, Amgen\nVinod Bulusu\, Executive Director\, Product Stewardship Lead\, AstraZeneca\nGiorgia Vicentini\, Vice President\, Global Program Lead\, Oncology\, Bristol Myers Squibb\nRonald Fleming\, Executive Director\, Clinical Development\, Daiichi Sankyo\nGail Lewis\, Distinguished Scientist\, Discovery Oncology\, Genentech\nMin Hu\, Senior Vice President\, Discovery\, Innovent Biologics\nBob Lutz\, Chief Scientific Officer\, Iksuda Therapeutics\nJeffrey Settleman\, Chief Scientific Officer\, Oncology R&D\, Pfizer\nDominik Schumacher\, Chief Executive Officer\, Tubulis\nRita Nanda\, Associate Professor\, Medicine & Director\, Breast Oncology\, Section of Hematology/Oncology\, University of Chicago\n\nView the full list of speaking companies: https://ter.li/xsz013cs \nIf you want to stay competitive in the field\, you cannot miss World ADC San Diego to de-risk future ADC development and push ADCs to earlier-line oncology treatments.
URL:http://www.pharmajournalist.com/event/17th-world-adc-san-diego/
LOCATION:Town & Country San Diego\, 500 Hotel Circle\, North San Diego\, San Diego\, CA\, 92108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR